310 Mira Street, Stavropol, Russia, 355017
+7 8652 352524; +7 8652 353229.
+7 8652 352524.
The journal is included into The list of leading scientific periodicals.
Using histological, immunohistochemical (IHC) and morphometric methods, B- and T-cells, we studied the spleens of 30 patients with aplastic anemia (AA). The median age is 21.0 (18.5; 38.5) years. The control group consisted of 20 persons who died suddenly and who did not have a history of blood diseases. In the histological material of the spleens, with IHC staining and morphometry, the relative numerical values of B-cells and T-cells populations in the functional areas of the organ in AA patients were obtained. Recalculation of morphometric parameters in absolute values (g) taking into account the mass of the spleen was carried out according to the original methodology. Evaluation of the content of B- and T-cells in the spleen made it possible to determine the factors predicting the course of development of AA after splenectomy. Signs which determine the unfavorable prognosis for the progression of disease are as follows: the absolute number of CD4+ T-cells in the spleen is less than 5.4 g and the Mass Ratio Index (MRI) CD4+ / CD8+ T-cells is less than or equal to 1.0. Consequentially that justifies a need for an individual approach to further immunosuppressive therapy in this category of patients.
1. Lin F., Karwan M., Saleh B., Hodge D. L., Chan T. [et al.] IFN-γ causes aplastic anemia by altering hematopoietic stem/progenitor cell composition and disrupting lineage differentiation. Blood. 2014;124(25):3699-3708.https://doi.org/10.1182/blood-2014-01-549527
2. Bruin A. M., Demirel O., Hooibrink B., Brandts C. H., Nolte M. A. Interferon-γ impairs proliferation of hematopoietic stem cells in mice. Blood. 2013;121(18):3578-3585.https://doi.org/10.1182/blood-2012-05-432906
3. Mikhailova E. A., Savchenko V. G., Ustinova E. N., Vinogradova M. A., Kokhno A. V. [et al.] Splenectomy in programmed therapy for aplastic anemia. Terapevticheskiy arkhiv. – Therapeutic Archive. 2006;78(8):52-57.
4. Kordasti S., Costantini B., Seidl T., Abellan P. P., Llordella M. M. [et al.] Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood. 2016; 128 (9):1193-1205.https://doi.org/10.1182/blood-2016-03-703702
5. Latour R. P., Visconte V. , Takaku T., Wu C., Erie A. J. [et al.] Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood. 2010;116(20):4175-4184.https://doi.org/10.1182/blood-2010-01-266098
6. Shi J., Ge M., Lu S., Li X., Shao Y., Huang J. [et al.] Intrinsic impairment of CD4+CD25+ regulatory T-cells in acquired aplastic anemia. Blood. 2012;120(8):1624-1632.https://doi.org/10.1182/blood-2011-11-390708
7. Ren J., Hou X. Y., Ma S. H., Zhang F. K., Zhen J. H. [et al.] Elevated expression of CX3C chemokine receptor 1 mediates recruitment of T cells into bone marrow of patients with acquired aplastic anemia. Journal of Internal Medicine. 2014;276(5):512-524. https://doi.org/10.1111/joim.12218
Keywords: human spleen, B-cells, T-cells, aplastic anemia